Avience Biomedicals IPO Subscription Status Day 1: Issue Booked 1.86 Times, Retail Portion Subscribed 2.90 Times

Mumbai, June 18: Following the opening of its initial public offering for subscription, Avience Biomedicals IPO witnessed healthy investor participation on the first day of bidding. The NSE SME issue was subscribed 1.86 times on Thursday, supported by strong demand from retail and non-institutional investors.

The ₹30.24 crore public issue opened for subscription on June 18, 2026, and will remain available for bidding until June 22, 2026. Avience Biomedicals is offering shares in a price band of ₹196 to ₹208 per share through a completely fresh issue of 14,53,800 equity shares.

Avience Biomedicals IPO Subscription Status Today

According to exchange data available as of 10:54 AM on Day 1, the IPO received bids for 17,91,000 shares against 9,61,800 shares on offer, resulting in an overall subscription of 1.86 times.

The retail investor category emerged as the strongest segment during early bidding activity.

Within the NII segment, the bNII portion was subscribed 1.83 times, while the sNII category was subscribed 2.08 times.

Retail Investors Lead Demand

Retail investors showed the highest interest in the issue during the opening session. The retail portion was subscribed 2.90 times after receiving bids for 13,94,400 shares against 4,81,200 shares reserved for the category.

The strong response from retail investors helped the issue cross full subscription within hours of opening.

NII Portion Also Sees Healthy Participation

The non-institutional investor category was subscribed 1.92 times on Day 1. The segment received bids for 3,96,600 shares against 2,07,000 shares available for allocation.

Demand was relatively balanced across both bNII and sNII categories, indicating participation from different investor groups.

QIB Participation Yet To Pick Up

The Qualified Institutional Buyer (QIB) portion, excluding anchor investors, had not received bids as of the latest update. Institutional participation in SME IPOs often increases closer to the final days of the subscription period.

Ahead of the issue opening, the company allotted 4,09,800 shares to anchor investors at ₹208 per share.

Avience Biomedicals IPO Details

The IPO comprises a fresh issue of 14,53,800 equity shares aggregating up to ₹30.24 crore.

Key details of the issue include:

• Price Band: ₹196 to ₹208 per share
• Issue Size: ₹30.24 crore
• Lot Size: 600 shares
• Minimum Retail Application: 1,200 shares
• Listing Platform: NSE SME
• IPO Closing Date: June 22, 2026
• Tentative Listing Date: June 25, 2026

At the upper price band, retail investors need a minimum investment of ₹2,49,600 for one application.

About Avience Biomedicals

Avience Biomedicals operates in the healthcare sector and provides solutions within the biomedical and healthcare ecosystem. The company is accessing the capital markets through the SME route to support its growth plans and business expansion initiatives.

Finetellectual Corporate Advisors Pvt. Ltd. is the book-running lead manager to the issue, while Skyline Financial Services Pvt. Ltd. serves as the registrar.

Conclusion

Avience Biomedicals IPO made a strong start on Day 1, with the issue subscribed 1.86 times within the first few hours of opening. Robust retail participation and healthy NII demand helped drive the early response, while investors will continue to monitor subscription trends as the IPO remains open for bidding until June 22, 2026.

Source:

• https://www.chittorgarh.net/reports/anchor-investor/aviencebiomedicals_anchorallocationreport.pdf